MX2023009100A - Agentes aglutinantes y métodos para usar los mismos. - Google Patents

Agentes aglutinantes y métodos para usar los mismos.

Info

Publication number
MX2023009100A
MX2023009100A MX2023009100A MX2023009100A MX2023009100A MX 2023009100 A MX2023009100 A MX 2023009100A MX 2023009100 A MX2023009100 A MX 2023009100A MX 2023009100 A MX2023009100 A MX 2023009100A MX 2023009100 A MX2023009100 A MX 2023009100A
Authority
MX
Mexico
Prior art keywords
binding agents
methods
same
disease
kir
Prior art date
Application number
MX2023009100A
Other languages
English (en)
Spanish (es)
Inventor
Courtney Crane
Kristine Swiderek
Susan Julien
Original Assignee
Mozart Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mozart Therapeutics Inc filed Critical Mozart Therapeutics Inc
Publication of MX2023009100A publication Critical patent/MX2023009100A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023009100A 2021-02-03 2022-02-02 Agentes aglutinantes y métodos para usar los mismos. MX2023009100A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163145394P 2021-02-03 2021-02-03
US202163148016P 2021-02-10 2021-02-10
US202163161325P 2021-03-15 2021-03-15
US202163209949P 2021-06-11 2021-06-11
US202263298028P 2022-01-10 2022-01-10
PCT/US2022/014881 WO2022169825A1 (en) 2021-02-03 2022-02-02 Binding agents and methods of using the same

Publications (1)

Publication Number Publication Date
MX2023009100A true MX2023009100A (es) 2023-09-25

Family

ID=80447069

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009100A MX2023009100A (es) 2021-02-03 2022-02-02 Agentes aglutinantes y métodos para usar los mismos.

Country Status (9)

Country Link
US (2) US20240101673A1 (enExample)
EP (1) EP4288455A1 (enExample)
JP (1) JP2024505600A (enExample)
KR (1) KR20230152032A (enExample)
AU (1) AU2022218137A1 (enExample)
CA (1) CA3209479A1 (enExample)
IL (1) IL304736A (enExample)
MX (1) MX2023009100A (enExample)
WO (1) WO2022169825A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11254744B2 (en) * 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
WO2023076876A1 (en) * 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2024243423A1 (en) 2023-05-24 2024-11-28 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
WO2025222129A2 (en) 2024-04-19 2025-10-23 Mozart Therapeutics, Inc. Engineered cytokines and targeted cytokine delivery

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6106834A (en) 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
AU1908395A (en) 1994-01-28 1995-08-15 Board Of Trustees Of The Leland Stanford Junior University Antibodies to mammalian natural killer antigens and uses
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CN1247472A (zh) 1997-01-10 2000-03-15 拜奥根有限公司 用抗cd40l化合物治疗狼疮性肾炎
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US20030167531A1 (en) 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
US6512162B2 (en) 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0014945A (pt) 1999-10-21 2004-08-31 Monsanto Co Modificação pós-traducional de proteìnas recombinantes produzidas em plantas
CA2390412A1 (en) 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
WO2003048327A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
US20080254027A1 (en) 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
HRP20120845T1 (hr) 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US10000574B2 (en) 2003-11-28 2018-06-19 Amgen Research (Munich) Gmbh Compositions comprising polypeptides
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US20050266001A1 (en) 2004-04-02 2005-12-01 Hadley Gregg A Therapeutic blockade of CD103 interactions to prevent clinical renal allograft rejection
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
ES2665422T3 (es) 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
CN101300272B (zh) 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2007063825A1 (ja) 2005-11-29 2007-06-07 Japan Science And Technology Agency Cd166に対するモノクローナル抗体およびその産生方法
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CN105037549B (zh) 2007-01-11 2018-09-28 诺和诺德公司 抗-kir抗体、制剂及其应用
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
AU2008247382B2 (en) 2007-05-07 2014-06-05 Medimmune, Llc Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
MX338397B (es) 2007-08-29 2016-04-15 Sanofi Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
EP2238170B1 (en) 2008-01-31 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RU2011111640A (ru) 2008-08-29 2012-10-10 Симфоген А/С (Dk) Антитела против cd5
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
ES2539045T3 (es) 2009-01-19 2015-06-25 Innate Pharma Anticuerpos anti-KIR3D
EP2560994B1 (en) 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
CA2809089C (en) 2010-08-23 2018-12-18 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
WO2012054509A2 (en) 2010-10-22 2012-04-26 Dana-Farber Cancer Institute, Inc. Discovery of regulatory t cells programmed to suppress an immune response
EP2643350A4 (en) 2010-11-22 2015-01-07 Innate Pharma Sa TREATMENTS WITH NK CELL MODULATION AND METHOD FOR THE TREATMENT OF HEMATOLOGICAL MALIGNOMES
EP2654789B1 (en) 2010-12-22 2018-05-30 Orega Biotech Antibodies against human cd39 and use thereof
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
ES2765874T3 (es) * 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
NO2748201T3 (enExample) 2011-08-23 2018-05-12
WO2013109974A2 (en) 2012-01-20 2013-07-25 Genzyme Corporation Anti-cxcr3 antibodies
US20130216540A1 (en) 2012-02-22 2013-08-22 The Uab Research Foundation Modulation of the innate immune system through the trem-like transcript 2 protein
US20150344580A1 (en) 2012-06-05 2015-12-03 Eldar Kim Human Monoclonal Antibodies Against Human Chemokine Receptor CCR7
MX369148B (es) 2012-09-19 2019-10-30 Innate Pharma Agentes de unión kir3dl2.
PL2904011T3 (pl) 2012-10-02 2018-01-31 Bristol Myers Squibb Co Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
EP2912063A1 (en) * 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
ES2707057T3 (es) * 2013-11-06 2019-04-02 Bristol Myers Squibb Co Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
EA201790437A1 (ru) 2014-08-22 2017-08-31 Сорренто Терапьютикс, Инк. Антигенсвязывающие белки, связывающиеся с cxcr3
MA40527A (fr) 2014-08-22 2017-06-28 Sorrento Therapeutics Inc Protéines de liaison à l'antigène se liant à wisp5
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
SI3215532T1 (sl) 2014-11-06 2020-02-28 F. Hoffmann-La Roche Ag Protitelesa proti TIM3 in postopki uporabe
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
US10786549B2 (en) 2015-04-23 2020-09-29 Baylor College Of Medicine CD5 chimeric antigen receptor for adoptive T cell therapy
IL292798A (en) 2015-05-04 2022-07-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
CA2988119A1 (en) * 2015-06-03 2016-12-08 Dana-Farber Cancer Institute, Inc. Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
DK3334457T3 (da) 2015-08-10 2020-09-21 Pepmab B V Humaniserede anti-CCR7-receptorantistoffer
EP3349793B1 (en) 2015-09-14 2021-08-11 Université Laval Anti-s100a8 for treating leukemia
WO2017106684A2 (en) 2015-12-17 2017-06-22 Janssen Biotech, Inc. Antibodies specifically binding hla-dr and their uses
KR20180096789A (ko) 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
US10668180B2 (en) 2016-03-02 2020-06-02 Asp Global Manufacturing Gmbh Apparatus and method for sterilizing medical devices
EP4063858A1 (en) 2016-03-14 2022-09-28 Biogen International Neuroscience GmbH Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins
AU2016402264B2 (en) 2016-04-15 2024-08-22 Pontificia Universidad Católica De Chile Pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and the use thereof
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
RU2754058C2 (ru) 2016-12-13 2021-08-26 Астеллас Фарма Инк. Антитело к cd73 человека
EP3565841A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
CA3052291A1 (en) 2017-02-09 2018-08-16 Memorial Sloan Kettering Cancer Center Anti-kir3dl1 antibodies
EP3586869A4 (en) 2017-02-21 2021-01-06 Osaka University IMMUNOGENIC COMPOSITION TARGETED FOR S100A9
US10577421B2 (en) 2017-02-22 2020-03-03 I-Mab Anti-LAG-3 antibodies and uses thereof
KR102294136B1 (ko) 2017-04-05 2021-08-26 에프. 호프만-라 로슈 아게 항-lag3 항체
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
US11530273B2 (en) 2017-05-23 2022-12-20 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
MY202018A (en) 2017-07-31 2024-03-29 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
CN111511763B (zh) * 2017-08-09 2024-05-31 奥里尼斯生物科学有限公司 Cd8结合剂
US11059892B2 (en) 2017-08-11 2021-07-13 Research Development Foundation Engineered antibody Fc variants for enhanced serum half life
TWI701259B (zh) 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
CN111615520A (zh) 2017-12-01 2020-09-01 辉瑞大药厂 抗cxcr5抗体及其组合物和用途
AU2019241240A1 (en) 2018-03-28 2020-10-29 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD27 antibody, antigen-binding fragment thereof and medical use thereof
JP2022510218A (ja) 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
JP2022538139A (ja) 2019-07-02 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体
AU2020325027A1 (en) * 2019-08-05 2022-03-03 The Board Of Trustees Of The Leland Stanford Junior University Manipulation and use of antigen-specific regulatory T cells
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors

Also Published As

Publication number Publication date
US20250026830A1 (en) 2025-01-23
KR20230152032A (ko) 2023-11-02
AU2022218137A1 (en) 2023-08-24
US20240101673A1 (en) 2024-03-28
WO2022169825A1 (en) 2022-08-11
CA3209479A1 (en) 2022-08-11
EP4288455A1 (en) 2023-12-13
IL304736A (en) 2023-09-01
JP2024505600A (ja) 2024-02-06
US12269883B2 (en) 2025-04-08

Similar Documents

Publication Publication Date Title
MX2023009100A (es) Agentes aglutinantes y métodos para usar los mismos.
MX2025009222A (es) Agentes de union a clec9a y su uso
CL2018000908A1 (es) Anticuerpos anti-lag3 y su uso para tratar cáncer o infección viral.
MX2020009568A (es) Anticuerpos que se unen a cd39 y sus usos.
CL2021000088A1 (es) Anticuerpos anti-cd27 (divisional de solicitud 779-2019).
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
CL2017001920A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
MX2025003354A (es) Anticuerpos que se unen a 5t4
AR091305A1 (es) ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
AR105489A1 (es) Anticuerpos pd-1
GT200900188A (es) Anticuerpos neutralizantes del citomegalovirus humano y su uso.
MX2017007973A (es) Tratamiento de penfigo.
UY35417A (es) Anticuerpos dirigidos contra il-33 y sus usos.
MX2017008875A (es) Anticuerpos biespecificos contra cd3 y cd20.
EP4527922A3 (en) Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
UY34988A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso
CL2015002603A1 (es) Anticuerpos humanos contragrem1.
CO2023008643A2 (es) Anticuerpos anti-hla-g y uso de estos
ECSP18009949A (es) Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
CO2022009205A2 (es) Anticuerpos anti-ccl2 biespecíficos